RPS6KA2 Antibody (C-Term, near)
Peptide-affinity purified goat antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q15349 |
Other Accession | NP_066958.2, NP_001006933.1, 6196 |
Reactivity | Rat |
Predicted | Human, Mouse, Horse |
Host | Goat |
Clonality | Polyclonal |
Concentration | 0.5 mg/ml |
Isotype | IgG |
Calculated MW | 83239 Da |
Gene ID | 6196 |
---|---|
Other Names | Ribosomal protein S6 kinase alpha-2, S6K-alpha-2, 2.7.11.1, 90 kDa ribosomal protein S6 kinase 2, p90-RSK 2, p90RSK2, MAP kinase-activated protein kinase 1c, MAPK-activated protein kinase 1c, MAPKAP kinase 1c, MAPKAPK-1c, Ribosomal S6 kinase 3, RSK-3, pp90RSK3, RPS6KA2, MAPKAPK1C, RSK3 |
Format | 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | RPS6KA2 Antibody (C-Term, near) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RPS6KA2 |
---|---|
Synonyms | MAPKAPK1C, RSK3 |
Function | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. May function as tumor suppressor in epithelial ovarian cancer cells. |
Cellular Location | Nucleus. Cytoplasm |
Tissue Location | Widely expressed with higher expression in lung, skeletal muscle, brain, uterus, ovary, thyroid and prostate |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This antibody is expected to recognize both reported isoforms (NP_066958.2; NP_001006933.1)
References
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J Cancer Cell. 2007 Sep;12(3):201-14 PMID: 17785202
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.